The US Patent and Trademark Office grants Brighter's patent to securely combine MDD and IVDD into one unit

The US Patent and Trademark Office grants Brighter's patent for a safety mechanism when combining injection functionality which is regulated under MDD ("Medical Device Directive") and diagnostic technology which is regulated under IVDD ("In-Vitro Diagnostics Directive") into one unit. The patent is an extension of Brighter's main patent. The company thereby strengthens its protection for combination solutions and the collection of unique valid treatment data in the US, one of the largest markets for Actiste® Diabetes Management as a Service, which is the Brighter's first application based on the patent.

“The United States is one of the largest and most important markets in the long term and our IP portfolio secures a unique position in the US market. We are the only company that can provide the patients, healthcare institutions and pharmaceutical companies a complete and valid overall picture with unique data based on the combination of MDD and IVDD. Within diabetes but also in other treatment areas where drugs are injected,” says Truls Sjöstedt, Brighter's Executive Chairman of the Board.

Actiste is the world's first complete IoT care solution for monitoring and treating insulin-dependent diabetes. The unit brings together and combine all the necessary functions for diabetes care – blood sampling, blood glucose measurement and drug injection – in a single connected device. The solution is based on patented technology for collecting data on specified biomarkers and injected volumes of drugs. With state-of-the-art eSIM technology, Actiste has global out-of-the-box connectivity, which means that it is completely independent of other devices for sharing health and treatment data. Actiste received two CE-marks in September 2019 - one for MDD and one for IVDD.

The Actiste device is delivered as part of a subscription service. The service includes global connectivity, different levels of data sharing, continuous and automatic replenishment of consumables, and enables coaching and guidance to optimize and improve treatment. https://actiste.com/

For further information, please contact:

Truls Sjöstedt, Executive Chairman of the Board
Telephone: +46 729 99 38 60   
Email: truls.sjostedt@brighter.se

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/

The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.

About Us

Brighter is a Swedish health-tech company with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/ The Company's shares are listed on Nasdaq First North Growth Market/BRIG. Brighter’s Certified Adviser is Eminova Fondkommission AB +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se

Subscribe

Documents & Links